Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medical Developments International Limited (MVP.AX)
AUD0.41
+0.00 (+0.00%)
AU ASX Healthcare Drug Manufacturers - Specialty & Generic
Address
4 Caribbean Drive 3179
Scoresby, VIC, AU
Scoresby, VIC, AU
CEO
Brent MacGregor
Website
medicaldev.com
IPO
2003-12-14
ISIN AU000000MVP2
Also trades on
Australian Securities Exchange · MVP.AX (AUD)
Other OTC · MDDVF (USD)
Description
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.41
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
162.5K
Beta
1.39
Float Shares
97.74M
Free Float %
86.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.28% | -3.75% | -12.50% | -13.48% | -26.67% | -30.63% | -42.54% | -54.65% | -91.77% | -93.76% | -18.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.41
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.30
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+17.8% ★ Q4'25: +43.0% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.2% ★ Q4'25: +98.3% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-0.2% Q4'25: +0.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.4% Q4'25: -0.2% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.2% Q4'25: -0.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+30.0% Q4'25: +27.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.19× ★ Q4'25: 0.63× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 2 EPS Ana. |
Jun 2027 2 Rev. Ana. 2 EPS Ana. |
Jun 2028 2 Rev. Ana. 2 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.37M
est: 9.44M (-0.7%)
|
11.61M
est: 11.40M (+1.8%)
|
15.47M
est: 15.35M (+0.8%)
|
18.35M
est: 18.25M (+0.5%)
|
17.46M
est: 17.83M (-2.1%)
|
20.88M
est: 20.40M (+2.3%)
|
22.54M
est: 24.25M (-7.1%)
|
25.27M
est: 26.30M (-3.9%)
|
21.94M
est: 22.10M (-0.7%)
|
32.34M
est: 30.10M (+7.4%)
|
33.15M
est: 33.20M (-0.2%)
|
39.06M
est: 39.10M (-0.1%)
|
42.80M
42.00M – 43.60M
+9.5% YoY
|
47.45M
47.10M – 47.80M
+10.9% YoY
|
52.55M
51.88M – 53.22M
+10.7% YoY
|
58.70M
57.95M – 59.45M
+11.7% YoY
|
| EBITDA |
959.0K
est: -3.78M (+125.4%)
|
2.63M
est: -4.57M (+157.7%)
|
3.42M
est: -6.15M (+155.6%)
|
3.80M
est: 2.89M (+31.5%)
|
2.22M
est: 2.38M (-6.7%)
|
3.89M
est: 358.1K (+985.8%)
|
3.03M
est: 1.66M (+82.2%)
|
-11.11M
est: 416.8K (-2,765.5%)
|
-12.86M
est: 554.2K (-2,420.6%)
|
-4.28M
est: 1.06M (-502.3%)
|
-29.45M
est: 1.75M (-1,786.0%)
|
1.67M
est: -15.67M (+110.7%)
|
-17.15M
-17.47M – -16.83M
-9.5% YoY
|
-19.01M
-19.15M – -18.87M
-10.9% YoY
|
-21.06M
-21.33M – -20.79M
-10.7% YoY
|
-23.52M
-23.82M – -23.22M
-11.7% YoY
|
| EBIT |
797.0K
est: -4.77M (+116.7%)
|
2.23M
est: -5.75M (+138.8%)
|
2.31M
est: -7.75M (+129.8%)
|
2.47M
est: 2.89M (-14.6%)
|
441.0K
est: 2.38M (-81.5%)
|
1.62M
est: 358.1K (+353.0%)
|
435.0K
est: 1.66M (-73.9%)
|
-14.86M
est: 416.8K (-3,665.0%)
|
-15.81M
est: 554.2K (-2,952.0%)
|
-7.40M
est: 1.06M (-794.6%)
|
-32.84M
est: 1.75M (-1,980.4%)
|
141.0K
est: -19.74M (+100.7%)
|
-21.61M
-22.01M – -21.20M
-9.5% YoY
|
-23.95M
-24.13M – -23.78M
-10.9% YoY
|
-26.53M
-26.87M – -26.19M
-10.7% YoY
|
-29.63M
-30.01M – -29.25M
-11.7% YoY
|
| Net Income |
875.0K
est: 1.59M (-44.8%)
|
1.53M
est: 2.26M (-32.3%)
|
1.57M
est: 4.89M (-67.9%)
|
1.82M
est: 1.97M (-7.7%)
|
243.0K
est: 1.76M (-86.2%)
|
1.04M
est: 289.1K (+259.1%)
|
379.0K
est: 1.11M (-66.0%)
|
-12.57M
est: 492.1K (-2,653.4%)
|
-12.41M
est: 654.3K (-1,996.2%)
|
-5.61M
est: -5.61M (+0.0%)
|
-40.99M
est: -40.99M (+0.0%)
|
94.0K
est: -1.27M (+107.4%)
|
-1.15M
-1.57M – -785.1K
+9.3% YoY
|
1.30M
785.1K – 1.79M
+213.0% YoY
|
3.60M
2.36M – 4.71M
+176.9% YoY
|
9.87M
9.71M – 10.03M
+174.2% YoY
|
| SGA |
4.21M
est: 9.12M (-53.8%)
|
4.18M
est: 6.34M (-34.1%)
|
6.64M
est: 14.82M (-55.2%)
|
8.01M
est: 9.92M (-19.3%)
|
9.33M
est: 8.75M (+6.5%)
|
9.67M
est: 11.65M (-17.0%)
|
10.97M
est: 11.17M (-1.8%)
|
21.38M
est: 15.65M (+36.6%)
|
24.81M
est: 20.82M (+19.2%)
|
36.40M
est: 29.07M (+25.2%)
|
35.09M
est: 32.06M (+9.5%)
|
26.08M
est: 37.76M (-30.9%)
|
41.33M
40.56M – 42.11M
+9.5% YoY
|
45.82M
45.49M – 46.16M
+10.9% YoY
|
50.75M
50.10M – 51.40M
+10.7% YoY
|
56.69M
55.97M – 57.41M
+11.7% YoY
|
| EPS |
0.02
est: 0.01 (+7.5%)
|
0.03
est: 0.02 (+31.6%)
|
0.03
est: 0.04 (-37.9%)
|
0.03
est: 0.04 (-13.8%)
|
0.00
est: 0.03 (-84.2%)
|
0.02
est: 0.01 (+83.1%)
|
0.01
est: 0.01 (-48.3%)
|
-0.18
est: -0.18 (+0.7%)
|
-0.17
est: -0.17 (+2.6%)
|
-0.07
est: -0.29 (+77.2%)
|
-0.47
est: -0.33 (-42.4%)
|
0.00
est: -0.01 (+108.0%)
|
-0.01
-0.01 – -0.01
+7.1% YoY
|
0.01
0.01 – 0.02
+209.5% YoY
|
0.03
0.02 – 0.04
+173.9% YoY
|
0.09
0.09 – 0.09
+179.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.01M
OE per share TTM
0.00
Owner's Yield
2.33%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
38.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.1K
Shares Outstanding
112.66M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brent MacGregor | Chief Executive Officer | 860.5K | male |
| Anita James | Chief Financial Officer | 485.3K | female |
| Benson Lee | Head of Commercial Operations | — | male |
| Jas Singh | Global Head of Respiratory | — | male |
| Julianne Alexander | Head of Medical Affairs, Regulatory Affairs & Clinical Development | — | female |
| Scott Courtney | Chief Scientific Officer | — | — |
| Stefaan Schatteman | Head of Europe | — | male |
| Tara Eaton | General Counsel & Company Secretary | — | female |
| Anastasia Tan | Head of Operations & Supply Chain | — | female |
| Wayne Pearce | Head of Production | — | — |
| Anthony Wheal | Head of People & Culture | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MVP.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
